TerminatedNCT00299611
Augmentation Study of Levetiracetam in OCD
Medication studyAges 18–65United States
Understand this study
Who could participate?
This study is for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- DurhamSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNovember 2005
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 12
- Sponsor
- Duke University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00299611
- Official title
Show the full official title
A Double-Blind Augmentation Study of LEvetiracetam in Obsessive Compulsive Disorder
Recruitment & locations
TerminatedDurham
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Duke University, a university.
Does this study involve medication?
Yes. The study involves medication, including Sertraline, Levetiracetam and Placebo.
Who can participate?
This study is for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
